CA 19-9 Level as Indicator of Early Distant Metastasis and Therapeutic Selection in Resected Pancreatic Cancer
Purpose In patients with pancreatic cancer treated with curative resection, we evaluated the effect of clinicopathologic parameters on early distant metastasis within 6 months (DM6m ) to identify patients who might benefit from surgery. Methods and Materials The study involved 84 patients with pancr...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2011-12, Vol.81 (5), p.e743-e748 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e748 |
|---|---|
| container_issue | 5 |
| container_start_page | e743 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 81 |
| creator | Kim, Tae Hyun, M.D Han, Sung-Sik, M.D Park, Sang-Jae, M.D Lee, Woo Jin, M.D Woo, Sang Myung, M.D Yoo, Tae, M.D Moon, Sung Ho, M.D Kim, Seong Hoon, M.D Hong, Eun Kyung, M.D Kim, Dae Yong, M.D Park, Joong-Won, M.D |
| description | Purpose In patients with pancreatic cancer treated with curative resection, we evaluated the effect of clinicopathologic parameters on early distant metastasis within 6 months (DM6m ) to identify patients who might benefit from surgery. Methods and Materials The study involved 84 patients with pancreatic cancer who had undergone curative resection between August 2001 and April 2009. The parameters of gender, age, tumor size, histologic differentiation, T classification, N classification, pre- and postoperative carbohydrate antigen (CA) 19-9 level, resection margin, and adjuvant chemoradiotherapy were analyzed to identify the risk factors associated with DM6m. Results Of the 84 patients, locoregional recurrence developed in 35 (41.7%) and distant metastasis in 58 (69%). Of the 58 patients with distant metastasis, DM6m had developed in 27 (46.6%). Multivariate analysis showed that preoperative CA 19-9 level was significantly associated with DM6m ( p < .05). Of all 84 patients, DM6m was observed in 9.1%, 50%, and 80% of those with a preoperative CA 19-9 level of ≤100 U/mL, 101–400 U/mL, and >400 U/mL, respectively ( p < .001). Conclusions The preoperative CA 19-9 level might be a useful predictor of DM6m and to identify those who would benefit from surgical resection. |
| doi_str_mv | 10.1016/j.ijrobp.2010.10.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_22054482</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301610034292</els_id><sourcerecordid>906155183</sourcerecordid><originalsourceid>FETCH-LOGICAL-c510t-5ce2ecfeb8f753db151a887c0850fa697955fdf2bbcf5e18ba7fe7bd738eb2b13</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhi1ERZfCP0DIEgdOWWwn3jgXpGopUGmrVrRI3CzbGasOWXtrO5X23-OQwoELJ49Hz3zofQehN5SsKaGbD8PaDTHow5qR36k1ofQZWlHRdlXN-Y_naEXqDanqAp-ilykNhBSkbV6gU0Yp6wRvV8hvzzHtqg7v4BFGrBK-9L0zKoeIg8UXKo5H_MmlrHzGV5BViZJLWPke391DVAeYsjP4FkYw2QWPncffIJUP9PhGeRNBzcC2hBBfoROrxgSvn94z9P3zxd32a7W7_nK5Pd9VhlOSK26AgbGghW153WvKqRKiNURwYtWmazvObW-Z1sZyoEKr1kKr-7YWoJmm9Rl6t_QNKTuZjMtg7k3wvuwlGSO8aQQr1PuFOsTwMEHKcu-SgXFUHsKUZEc2lHMq6kI2C2liSCmClYfo9ioeJSVytkMOcrFDznbM2aJ1KXv7NGDSe-j_Fv3RvwAfFwCKGI8O4rwrFKV6F-dV--D-N-HfBmZ0vhg4_oQjpCFM0RehJZWJSSJv55OYL4ISUjesY_UvTAGyCQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>906155183</pqid></control><display><type>article</type><title>CA 19-9 Level as Indicator of Early Distant Metastasis and Therapeutic Selection in Resected Pancreatic Cancer</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Kim, Tae Hyun, M.D ; Han, Sung-Sik, M.D ; Park, Sang-Jae, M.D ; Lee, Woo Jin, M.D ; Woo, Sang Myung, M.D ; Yoo, Tae, M.D ; Moon, Sung Ho, M.D ; Kim, Seong Hoon, M.D ; Hong, Eun Kyung, M.D ; Kim, Dae Yong, M.D ; Park, Joong-Won, M.D</creator><creatorcontrib>Kim, Tae Hyun, M.D ; Han, Sung-Sik, M.D ; Park, Sang-Jae, M.D ; Lee, Woo Jin, M.D ; Woo, Sang Myung, M.D ; Yoo, Tae, M.D ; Moon, Sung Ho, M.D ; Kim, Seong Hoon, M.D ; Hong, Eun Kyung, M.D ; Kim, Dae Yong, M.D ; Park, Joong-Won, M.D</creatorcontrib><description>Purpose In patients with pancreatic cancer treated with curative resection, we evaluated the effect of clinicopathologic parameters on early distant metastasis within 6 months (DM6m ) to identify patients who might benefit from surgery. Methods and Materials The study involved 84 patients with pancreatic cancer who had undergone curative resection between August 2001 and April 2009. The parameters of gender, age, tumor size, histologic differentiation, T classification, N classification, pre- and postoperative carbohydrate antigen (CA) 19-9 level, resection margin, and adjuvant chemoradiotherapy were analyzed to identify the risk factors associated with DM6m. Results Of the 84 patients, locoregional recurrence developed in 35 (41.7%) and distant metastasis in 58 (69%). Of the 58 patients with distant metastasis, DM6m had developed in 27 (46.6%). Multivariate analysis showed that preoperative CA 19-9 level was significantly associated with DM6m ( p < .05). Of all 84 patients, DM6m was observed in 9.1%, 50%, and 80% of those with a preoperative CA 19-9 level of ≤100 U/mL, 101–400 U/mL, and >400 U/mL, respectively ( p < .001). Conclusions The preoperative CA 19-9 level might be a useful predictor of DM6m and to identify those who would benefit from surgical resection.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2010.10.011</identifier><identifier>PMID: 21129857</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Analysis of Variance ; ANTIGENS ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; CA 19-9 ; CA-19-9 Antigen - blood ; Capecitabine ; Carbohydrate antigen 19-9 ; CARBOHYDRATES ; Chemoradiotherapy ; CLASSIFICATION ; COMBINED THERAPY ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Distant metastasis ; Female ; Fluorouracil - administration & dosage ; Fluorouracil - analogs & derivatives ; HAZARDS ; Hematology, Oncology and Palliative Medicine ; Humans ; INDICATORS ; Leucovorin - administration & dosage ; Male ; METASTASES ; Middle Aged ; MULTIVARIATE ANALYSIS ; Neoplasm Metastasis ; NEOPLASMS ; PANCREAS ; Pancreatic cancer ; Pancreatic Neoplasms - blood ; Pancreatic Neoplasms - mortality ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - surgery ; Pancreatic Neoplasms - therapy ; PATIENTS ; Radiology ; RADIOLOGY AND NUCLEAR MEDICINE ; Radiotherapy Dosage ; Retrospective Studies ; SURGERY</subject><ispartof>International journal of radiation oncology, biology, physics, 2011-12, Vol.81 (5), p.e743-e748</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c510t-5ce2ecfeb8f753db151a887c0850fa697955fdf2bbcf5e18ba7fe7bd738eb2b13</citedby><cites>FETCH-LOGICAL-c510t-5ce2ecfeb8f753db151a887c0850fa697955fdf2bbcf5e18ba7fe7bd738eb2b13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2010.10.011$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,777,781,882,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21129857$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/22054482$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Tae Hyun, M.D</creatorcontrib><creatorcontrib>Han, Sung-Sik, M.D</creatorcontrib><creatorcontrib>Park, Sang-Jae, M.D</creatorcontrib><creatorcontrib>Lee, Woo Jin, M.D</creatorcontrib><creatorcontrib>Woo, Sang Myung, M.D</creatorcontrib><creatorcontrib>Yoo, Tae, M.D</creatorcontrib><creatorcontrib>Moon, Sung Ho, M.D</creatorcontrib><creatorcontrib>Kim, Seong Hoon, M.D</creatorcontrib><creatorcontrib>Hong, Eun Kyung, M.D</creatorcontrib><creatorcontrib>Kim, Dae Yong, M.D</creatorcontrib><creatorcontrib>Park, Joong-Won, M.D</creatorcontrib><title>CA 19-9 Level as Indicator of Early Distant Metastasis and Therapeutic Selection in Resected Pancreatic Cancer</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose In patients with pancreatic cancer treated with curative resection, we evaluated the effect of clinicopathologic parameters on early distant metastasis within 6 months (DM6m ) to identify patients who might benefit from surgery. Methods and Materials The study involved 84 patients with pancreatic cancer who had undergone curative resection between August 2001 and April 2009. The parameters of gender, age, tumor size, histologic differentiation, T classification, N classification, pre- and postoperative carbohydrate antigen (CA) 19-9 level, resection margin, and adjuvant chemoradiotherapy were analyzed to identify the risk factors associated with DM6m. Results Of the 84 patients, locoregional recurrence developed in 35 (41.7%) and distant metastasis in 58 (69%). Of the 58 patients with distant metastasis, DM6m had developed in 27 (46.6%). Multivariate analysis showed that preoperative CA 19-9 level was significantly associated with DM6m ( p < .05). Of all 84 patients, DM6m was observed in 9.1%, 50%, and 80% of those with a preoperative CA 19-9 level of ≤100 U/mL, 101–400 U/mL, and >400 U/mL, respectively ( p < .001). Conclusions The preoperative CA 19-9 level might be a useful predictor of DM6m and to identify those who would benefit from surgical resection.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis of Variance</subject><subject>ANTIGENS</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>CA 19-9</subject><subject>CA-19-9 Antigen - blood</subject><subject>Capecitabine</subject><subject>Carbohydrate antigen 19-9</subject><subject>CARBOHYDRATES</subject><subject>Chemoradiotherapy</subject><subject>CLASSIFICATION</subject><subject>COMBINED THERAPY</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Distant metastasis</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Fluorouracil - analogs & derivatives</subject><subject>HAZARDS</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>INDICATORS</subject><subject>Leucovorin - administration & dosage</subject><subject>Male</subject><subject>METASTASES</subject><subject>Middle Aged</subject><subject>MULTIVARIATE ANALYSIS</subject><subject>Neoplasm Metastasis</subject><subject>NEOPLASMS</subject><subject>PANCREAS</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - blood</subject><subject>Pancreatic Neoplasms - mortality</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic Neoplasms - surgery</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>PATIENTS</subject><subject>Radiology</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>Radiotherapy Dosage</subject><subject>Retrospective Studies</subject><subject>SURGERY</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkk1v1DAQhi1ERZfCP0DIEgdOWWwn3jgXpGopUGmrVrRI3CzbGasOWXtrO5X23-OQwoELJ49Hz3zofQehN5SsKaGbD8PaDTHow5qR36k1ofQZWlHRdlXN-Y_naEXqDanqAp-ilykNhBSkbV6gU0Yp6wRvV8hvzzHtqg7v4BFGrBK-9L0zKoeIg8UXKo5H_MmlrHzGV5BViZJLWPke391DVAeYsjP4FkYw2QWPncffIJUP9PhGeRNBzcC2hBBfoROrxgSvn94z9P3zxd32a7W7_nK5Pd9VhlOSK26AgbGghW153WvKqRKiNURwYtWmazvObW-Z1sZyoEKr1kKr-7YWoJmm9Rl6t_QNKTuZjMtg7k3wvuwlGSO8aQQr1PuFOsTwMEHKcu-SgXFUHsKUZEc2lHMq6kI2C2liSCmClYfo9ioeJSVytkMOcrFDznbM2aJ1KXv7NGDSe-j_Fv3RvwAfFwCKGI8O4rwrFKV6F-dV--D-N-HfBmZ0vhg4_oQjpCFM0RehJZWJSSJv55OYL4ISUjesY_UvTAGyCQ</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Kim, Tae Hyun, M.D</creator><creator>Han, Sung-Sik, M.D</creator><creator>Park, Sang-Jae, M.D</creator><creator>Lee, Woo Jin, M.D</creator><creator>Woo, Sang Myung, M.D</creator><creator>Yoo, Tae, M.D</creator><creator>Moon, Sung Ho, M.D</creator><creator>Kim, Seong Hoon, M.D</creator><creator>Hong, Eun Kyung, M.D</creator><creator>Kim, Dae Yong, M.D</creator><creator>Park, Joong-Won, M.D</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20111201</creationdate><title>CA 19-9 Level as Indicator of Early Distant Metastasis and Therapeutic Selection in Resected Pancreatic Cancer</title><author>Kim, Tae Hyun, M.D ; Han, Sung-Sik, M.D ; Park, Sang-Jae, M.D ; Lee, Woo Jin, M.D ; Woo, Sang Myung, M.D ; Yoo, Tae, M.D ; Moon, Sung Ho, M.D ; Kim, Seong Hoon, M.D ; Hong, Eun Kyung, M.D ; Kim, Dae Yong, M.D ; Park, Joong-Won, M.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c510t-5ce2ecfeb8f753db151a887c0850fa697955fdf2bbcf5e18ba7fe7bd738eb2b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis of Variance</topic><topic>ANTIGENS</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>CA 19-9</topic><topic>CA-19-9 Antigen - blood</topic><topic>Capecitabine</topic><topic>Carbohydrate antigen 19-9</topic><topic>CARBOHYDRATES</topic><topic>Chemoradiotherapy</topic><topic>CLASSIFICATION</topic><topic>COMBINED THERAPY</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Distant metastasis</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Fluorouracil - analogs & derivatives</topic><topic>HAZARDS</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>INDICATORS</topic><topic>Leucovorin - administration & dosage</topic><topic>Male</topic><topic>METASTASES</topic><topic>Middle Aged</topic><topic>MULTIVARIATE ANALYSIS</topic><topic>Neoplasm Metastasis</topic><topic>NEOPLASMS</topic><topic>PANCREAS</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - blood</topic><topic>Pancreatic Neoplasms - mortality</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic Neoplasms - surgery</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>PATIENTS</topic><topic>Radiology</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>Radiotherapy Dosage</topic><topic>Retrospective Studies</topic><topic>SURGERY</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Tae Hyun, M.D</creatorcontrib><creatorcontrib>Han, Sung-Sik, M.D</creatorcontrib><creatorcontrib>Park, Sang-Jae, M.D</creatorcontrib><creatorcontrib>Lee, Woo Jin, M.D</creatorcontrib><creatorcontrib>Woo, Sang Myung, M.D</creatorcontrib><creatorcontrib>Yoo, Tae, M.D</creatorcontrib><creatorcontrib>Moon, Sung Ho, M.D</creatorcontrib><creatorcontrib>Kim, Seong Hoon, M.D</creatorcontrib><creatorcontrib>Hong, Eun Kyung, M.D</creatorcontrib><creatorcontrib>Kim, Dae Yong, M.D</creatorcontrib><creatorcontrib>Park, Joong-Won, M.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Tae Hyun, M.D</au><au>Han, Sung-Sik, M.D</au><au>Park, Sang-Jae, M.D</au><au>Lee, Woo Jin, M.D</au><au>Woo, Sang Myung, M.D</au><au>Yoo, Tae, M.D</au><au>Moon, Sung Ho, M.D</au><au>Kim, Seong Hoon, M.D</au><au>Hong, Eun Kyung, M.D</au><au>Kim, Dae Yong, M.D</au><au>Park, Joong-Won, M.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CA 19-9 Level as Indicator of Early Distant Metastasis and Therapeutic Selection in Resected Pancreatic Cancer</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>81</volume><issue>5</issue><spage>e743</spage><epage>e748</epage><pages>e743-e748</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><abstract>Purpose In patients with pancreatic cancer treated with curative resection, we evaluated the effect of clinicopathologic parameters on early distant metastasis within 6 months (DM6m ) to identify patients who might benefit from surgery. Methods and Materials The study involved 84 patients with pancreatic cancer who had undergone curative resection between August 2001 and April 2009. The parameters of gender, age, tumor size, histologic differentiation, T classification, N classification, pre- and postoperative carbohydrate antigen (CA) 19-9 level, resection margin, and adjuvant chemoradiotherapy were analyzed to identify the risk factors associated with DM6m. Results Of the 84 patients, locoregional recurrence developed in 35 (41.7%) and distant metastasis in 58 (69%). Of the 58 patients with distant metastasis, DM6m had developed in 27 (46.6%). Multivariate analysis showed that preoperative CA 19-9 level was significantly associated with DM6m ( p < .05). Of all 84 patients, DM6m was observed in 9.1%, 50%, and 80% of those with a preoperative CA 19-9 level of ≤100 U/mL, 101–400 U/mL, and >400 U/mL, respectively ( p < .001). Conclusions The preoperative CA 19-9 level might be a useful predictor of DM6m and to identify those who would benefit from surgical resection.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>21129857</pmid><doi>10.1016/j.ijrobp.2010.10.011</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2011-12, Vol.81 (5), p.e743-e748 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_osti_scitechconnect_22054482 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Adult Aged Aged, 80 and over Analysis of Variance ANTIGENS Antineoplastic Combined Chemotherapy Protocols - therapeutic use CA 19-9 CA-19-9 Antigen - blood Capecitabine Carbohydrate antigen 19-9 CARBOHYDRATES Chemoradiotherapy CLASSIFICATION COMBINED THERAPY Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Distant metastasis Female Fluorouracil - administration & dosage Fluorouracil - analogs & derivatives HAZARDS Hematology, Oncology and Palliative Medicine Humans INDICATORS Leucovorin - administration & dosage Male METASTASES Middle Aged MULTIVARIATE ANALYSIS Neoplasm Metastasis NEOPLASMS PANCREAS Pancreatic cancer Pancreatic Neoplasms - blood Pancreatic Neoplasms - mortality Pancreatic Neoplasms - pathology Pancreatic Neoplasms - surgery Pancreatic Neoplasms - therapy PATIENTS Radiology RADIOLOGY AND NUCLEAR MEDICINE Radiotherapy Dosage Retrospective Studies SURGERY |
| title | CA 19-9 Level as Indicator of Early Distant Metastasis and Therapeutic Selection in Resected Pancreatic Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T09%3A34%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CA%2019-9%20Level%20as%20Indicator%20of%20Early%20Distant%20Metastasis%20and%20Therapeutic%20Selection%20in%20Resected%20Pancreatic%20Cancer&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Kim,%20Tae%20Hyun,%20M.D&rft.date=2011-12-01&rft.volume=81&rft.issue=5&rft.spage=e743&rft.epage=e748&rft.pages=e743-e748&rft.issn=0360-3016&rft.eissn=1879-355X&rft_id=info:doi/10.1016/j.ijrobp.2010.10.011&rft_dat=%3Cproquest_osti_%3E906155183%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=906155183&rft_id=info:pmid/21129857&rft_els_id=S0360301610034292&rfr_iscdi=true |